US Stock MarketDetailed Quotes
MBIO Mustang Bio
- 0.2051
- -0.0028-1.35%
Close Nov 22 16:00 ET
- 0.2010
- -0.0041-2.00%
Post 19:29 ET
9.80MMarket Cap-154P/E (TTM)
0.2122High0.2017Low412.45KVolume0.2030Open0.2079Pre Close85.41KTurnover0.93%Turnover RatioLossP/E (Static)47.78MShares1.678152wk High-1.13P/B9.08MFloat Cap0.128152wk Low--Dividend TTM44.28MShs Float200.2500Historical High--Div YieldTTM5.05%Amplitude0.1281Historical Low0.2070Avg Price1Lot Size
Mustang Bio Stock Forum
Sign in to post a comment
$Mustang Bio (MBIO.US)$ Reuters· just
Mustang Bio Inc - Extension Granted to Meet $1.00 Bid Price Requirement Through Jan 31, 2025
Mustang Bio Inc - Extension Granted to Meet $1.00 Bid Price Requirement Through Jan 31, 2025
2
4
$Mustang Bio (MBIO.US)$
Mustang Bio Receives Positive Listing Determination from Nasdaq
Mustang Bio (MBIO) has received a positive determination from the Nasdaq Hearings Panel, granting an extension to meet continued listing requirements. The company must achieve a $1.00 minimum bid price by January 31, 2025, and demonstrate $2.5 million stockholders' equity by February 18, 2025. While exploring options to maintain its Nasdaq listing, the company acknowledges there's no guarantee of meeting ...
Mustang Bio Receives Positive Listing Determination from Nasdaq
Mustang Bio (MBIO) has received a positive determination from the Nasdaq Hearings Panel, granting an extension to meet continued listing requirements. The company must achieve a $1.00 minimum bid price by January 31, 2025, and demonstrate $2.5 million stockholders' equity by February 18, 2025. While exploring options to maintain its Nasdaq listing, the company acknowledges there's no guarantee of meeting ...
1
$Mustang Bio (MBIO.US)$
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Mustang Bio (MBIO) has received Orphan Drug Designation from the FDA for MB-108, an HSV-1 oncolytic virus targeting malignant glioma. The designation provides tax credits, fee waivers, and seven years of market exclusivity upon approval. The company plans to combine MB-108 with MB-101 (IL13Rα2‐targeted CAR-T cell therapy) in a novel therapeutic approach...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Mustang Bio (MBIO) has received Orphan Drug Designation from the FDA for MB-108, an HSV-1 oncolytic virus targeting malignant glioma. The designation provides tax credits, fee waivers, and seven years of market exclusivity upon approval. The company plans to combine MB-108 with MB-101 (IL13Rα2‐targeted CAR-T cell therapy) in a novel therapeutic approach...
2
3
$Mustang Bio (MBIO.US)$ still able to move up? or dead already?
$Mustang Bio (MBIO.US)$ blow up ☄️
1
$Mustang Bio (MBIO.US)$ time to shine!
2
$Mustang Bio (MBIO.US)$ keep going!
2
🫲$Mustang Bio (MBIO.US)$ looking a lot better
1
$Mustang Bio (MBIO.US)$ dead ?
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
71698736 : Does this mean that the company’s stock price must reach $1.00 by January 31, 2025, to meet market requirements; otherwise, it will delisted on the market? Anyone can explain it? I am appreciative of this.
Trytosaveabit OP 71698736 : They have until then to trade above 1.00 for 10 straight trading days! If not? They will have to do a R/S to get above that minimum price requirement to stay listed and not be sent to the OTC market
71698736 Trytosaveabit OP : Thank you
Trytosaveabit OP 71698736 : You’re very welcome! Hope I explained it well enough! I’m more of a talker than a writer! Hehehe! GL